^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HRAS overexpression

    i
    Other names: HRAS, HRAS1, Harvey rat sarcoma viral oncogene homolog
    Entrez ID:
    3265
    Related biomarkers:
    Mutation
    Others
    2ms
    A more efficient method for generating glioblastoma-multiforme model in mice using genome editing technology. (PubMed, Biochem Biophys Res Commun)
    A CRISPR/Cas9-based method for inducing GIC is much more efficient than a KO mice-based method. This study provides a promising framework for easily creating glioblastoma model in mice.
    Preclinical • Journal
    |
    HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    HRAS overexpression
    4ms
    FIT-001: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=270, Recruiting, Kura Oncology, Inc.
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • HRAS mutation • HRAS overexpression
    |
    Cabometyx (cabozantinib tablet) • KO-2806
    7ms
    FIT-001: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=270, Recruiting, Kura Oncology, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • HRAS mutation • HRAS overexpression
    |
    Cabometyx (cabozantinib tablet) • KO-2806
    8ms
    FIT-001: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=270, Not yet recruiting, Kura Oncology, Inc.
    New P1 trial • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • HRAS mutation • HRAS overexpression
    |
    Cabometyx (cabozantinib tablet) • KO-2806
    8ms
    Oncogenic Ras and ΔNp63α cooperate to recruit immunosuppressive polymorphonuclear myeloid-derived suppressor cells in a mouse model of squamous cancer pathogenesis. (PubMed, Front Immunol)
    ΔNp63α/v-ras-driven carcinomas expressed higher levels of chemokines implicated in recruitment of MDSCs compared to v-ras-initiated tumors, providing a heretofore undescribed link between ΔNp63α/HRAS-driven carcinomas and the development of an immunosuppressive TME. These results support the utilization of a genetic carcinogenesis model harboring specific genomic drivers of malignancy to study mechanisms underlying the development of local immunosuppression.
    Preclinical • Journal
    |
    HRAS (Harvey rat sarcoma viral oncogene homolog) • TP63 (Tumor protein 63)
    |
    NRAS G12 • HRAS overexpression
    10ms
    Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma. (PubMed, Front Oncol)
    One patient each was treated with immune checkpoint inhibition (Mixed Response) and combination therapies of tipifarnib and ADT (SD) and alpelisib and ADT (PR). Combination therapies, PI3K-inhibitors and immune therapy warrant further investigation, ideally in clinical trials. Future research should consider this rare subgroup of SDC.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • AR (Androgen receptor) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    PD-L1 expression • PIK3CA mutation • HRAS mutation • AR overexpression • AR expression • PIK3CA expression • HRAS overexpression • PIK3CA overexpression
    |
    Piqray (alpelisib) • Zarnestra (tipifarnib)
    10ms
    Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity. (PubMed, Cancer Res)
    Combined alpelisib and tipifarnib has potential to benefit >45% of R/M HNSCC patients. By blocking feedback reactivation of mTORC1, tipifarnib may prevent adaptive resistance to additional targeted therapies, enhancing their clinical utility.
    Journal • IO biomarker
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    PIK3CA mutation • HRAS mutation • HRAS overexpression
    |
    Piqray (alpelisib) • Zarnestra (tipifarnib)
    1year
    HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors. (PubMed, Front Endocrinol (Lausanne))
    Lenvatinib appears to be a highly effective drug for the treatment of NETs. The evaluation of HRAS expression in the tumor tissue might improve patient selection and optimize therapeutic outcome.
    Journal
    |
    HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    HRAS overexpression
    |
    Lenvima (lenvatinib)
    almost2years
    A phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with PIK3CA-mutated/amplified and/or HRAS-overexpressing recurrent/metastatic head and neck squamous cell carcinoma. (ASCO 2022)
    All observed/available data among each cohort will be evaluated before choosing the combination dose for a subsequent cohort. Enrollment into the PIK3CA cohort began in October 2021.
    Clinical • P1/2 data
    |
    KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    PIK3CA mutation • HRAS mutation • HRAS overexpression • PIK3CA overexpression
    |
    Piqray (alpelisib) • Zarnestra (tipifarnib)